Looking Back at 2022 & Moving Forward into 2023

Dear Friends of Medicines360 – Happy New Year! 

2023 is already off to a roaring start and Medicines360 is excited to share the inaugural edition of “All Access,” our newly launched bulletin. With drug prices in the U.S. continuing to rise, breakthrough products and essential medications have become even more unaffordable, particularly for people without health insurance. As a result, there is ever-increasing interest among industry leaders, philanthropy, and others in how to improve access to medicines. 

Designed to keep you informed of our activities, this quarterly publication will summarize milestones in our journey as a nonprofit pharma organization to close gaps in access and provide an informed perspective on solutions to improve the availability of critical medicines for women. Founded in 2009, Medicines360 has longevity as a leading nonprofit pharmaceutical organization. We develop medicines and devices that enable more women to get the medicines they need, while also advocating locally and at the federal level for transformative change.  

The turning of each new year is often a time for personal and professional reflection. As I recount the past year and look forward to the agenda for the year ahead, we have much to celebrate – yet more to do as well. While 2022 continued to be colored by the challenges of navigating Covid-19, it was also filled with enormous heart, imagination, and ingenuity from our staff and leadership to create the conditions that enabled our work to flourish. 2022 US Highlights include: 

  • Strengthening our collaboration with the Population Council to develop a Dual Prevention Pill (DPP), a single pill that includes a combined hormonal contraceptive and pre-exposure Prophylaxis for HIV (PrEP), preventing pregnancy and HIV infection. 
  • Expanding access to Liletta to 29 new FQHCs and reaching approximately 70,000 women in safety net clinics with our hormonal IUD, Liletta.  
  • Work towards achieving important new legislative action in support of nonprofit pharma. 
  • Launched commercial operations in Curae Pharma360, our for profit subsidiary dedicated to increasing access to generic medications. 
  • Launching our new website to more clearly convey the purpose of our work and the activities we’re undertaking. 

This year, we are incredibly excited to consider new products for our pipeline, which will address the unmet health needs of women in the US and other countries. We are also taking bold steps to ensure that we meet the needs of women in low- and middle-income countries by collaborating with the Hormonal IUD Access Group and a number of Ministries of Health to increase the distribution of AVIBELA™.  2022 Global Highlights include: 

  • Registering our hormonal IUD Avibela® in Rwanda and Uganda; bringing total global registrations to seven (joining Kenya, Madagascar, Nigeria, Tanzania, and Zambia). 
  • Working to secure additional manufacturing capacity to lower the cost of our hormonal IUD for low- and middle-income countries. 

In closing, I offer sincere gratitude to the many partners, funders and supporters that make this important work possible. We hope you find this first edition of “All Access” both informative and inspiring. For more information or to inquire about ways we might partner, please visit our website at medicines360.org, or contact us via email at access@medicines360.org

Best Wishes for a Healthy and Happy New Year! 


Tina Raine-Bennett 

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

Share This

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.